Trinity Biotech Enters Oncology Space: Acquisition of EpiCapture Boosts Growth Potential
Friday, Oct 25, 2024 8:51 am ET
Trinity Biotech plc (Nasdaq: TRIB), a leading commercial-stage biotechnology company, has made a strategic move into the oncology diagnostics market with the acquisition of EpiCapture Limited. This acquisition, announced on October 25, 2024, positions Trinity Biotech to address the growing need for accurate and non-invasive monitoring of prostate cancer progression.
Prostate cancer is a significant health concern, with approximately 1 in 8 men diagnosed during their lifetime in the U.S. alone. The cost of diagnosis and treatment is estimated at over $10 billion annually, highlighting the importance of effective monitoring and management of the disease. EpiCapture's innovative urine-based test offers a breakthrough approach to monitoring disease progression by using epigenetic analysis to detect DNA methylation patterns indicative of high-grade cancer.
The acquisition of EpiCapture aligns with Trinity Biotech's strategy of combining established capabilities with cutting-edge technologies to address large-scale, urgent, and important clinical issues. Trinity Biotech's manufacturing expertise and New York State Department of Health-certified Immco reference laboratory will enable the advancement of EpiCapture's epigenetic analysis technology, providing a less invasive and more accurate method of monitoring prostate cancer progression.
The acquisition is expected to have a significant impact on Trinity Biotech's financial projections. EpiCapture's revenue potential, although not yet fully realized, is anticipated to contribute positively to the company's overall financial outlook. The expected synergies between Trinity Biotech and EpiCapture include the ability to leverage Trinity Biotech's 30 years of experience in diagnostic product optimization and manufacturing to commercialize the EpiCapture test in the US and explore regulatory pathways for launching the test in additional markets.
The acquisition of EpiCapture also influences Trinity Biotech's market valuation and competitive position in the diagnostics industry. By entering the oncology diagnostics market, Trinity Biotech expands its product portfolio and strengthens its position as a provider of innovative diagnostic solutions. The company's rich history of bringing innovative diagnostic solutions to global markets gives investors confidence in its ability to successfully commercialize the EpiCapture test and improve the lives of patients.
In conclusion, Trinity Biotech's acquisition of EpiCapture Limited is a strategic move that positions the company to address the critical need for accurate and non-invasive monitoring of prostate cancer progression. The acquisition is expected to contribute positively to Trinity Biotech's financial projections, enhance its market valuation, and strengthen its competitive position in the diagnostics industry. As the company continues to leverage its established capabilities and cutting-edge technologies, it is well-positioned to capitalize on the growing demand for innovative diagnostic solutions in the oncology space.
Prostate cancer is a significant health concern, with approximately 1 in 8 men diagnosed during their lifetime in the U.S. alone. The cost of diagnosis and treatment is estimated at over $10 billion annually, highlighting the importance of effective monitoring and management of the disease. EpiCapture's innovative urine-based test offers a breakthrough approach to monitoring disease progression by using epigenetic analysis to detect DNA methylation patterns indicative of high-grade cancer.
The acquisition of EpiCapture aligns with Trinity Biotech's strategy of combining established capabilities with cutting-edge technologies to address large-scale, urgent, and important clinical issues. Trinity Biotech's manufacturing expertise and New York State Department of Health-certified Immco reference laboratory will enable the advancement of EpiCapture's epigenetic analysis technology, providing a less invasive and more accurate method of monitoring prostate cancer progression.
The acquisition is expected to have a significant impact on Trinity Biotech's financial projections. EpiCapture's revenue potential, although not yet fully realized, is anticipated to contribute positively to the company's overall financial outlook. The expected synergies between Trinity Biotech and EpiCapture include the ability to leverage Trinity Biotech's 30 years of experience in diagnostic product optimization and manufacturing to commercialize the EpiCapture test in the US and explore regulatory pathways for launching the test in additional markets.
The acquisition of EpiCapture also influences Trinity Biotech's market valuation and competitive position in the diagnostics industry. By entering the oncology diagnostics market, Trinity Biotech expands its product portfolio and strengthens its position as a provider of innovative diagnostic solutions. The company's rich history of bringing innovative diagnostic solutions to global markets gives investors confidence in its ability to successfully commercialize the EpiCapture test and improve the lives of patients.
In conclusion, Trinity Biotech's acquisition of EpiCapture Limited is a strategic move that positions the company to address the critical need for accurate and non-invasive monitoring of prostate cancer progression. The acquisition is expected to contribute positively to Trinity Biotech's financial projections, enhance its market valuation, and strengthen its competitive position in the diagnostics industry. As the company continues to leverage its established capabilities and cutting-edge technologies, it is well-positioned to capitalize on the growing demand for innovative diagnostic solutions in the oncology space.
Disclaimer: the above is a summary showing certain market information. AInvest is not responsible for any data errors, omissions or other information that may be displayed incorrectly as the data is derived from a third party source. Communications displaying market prices, data and other information available in this post are meant for informational purposes only and are not intended as an offer or solicitation for the purchase or sale of any security. Please do your own research when investing. All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit, or protect against loss in a down market.
I recently started working with Google remote jobs and I'm making around $550–$830 per week now. Honestly, I never thought it would be this easy to earn online. If anyone's serious, there are still openings available!
Get started today..... 𝐰𝐰𝐰.𝐉𝐨𝐛𝐬𝟔𝟕.𝐜𝐨𝐦
Don't invest blindly in stocks or crypto when you do not have a proper guide. I lost 30k trying to trade on my own but ever since Mrs Susan J Demirors stepped in, I have been making huge profits. I made over 450k since October. She is always available to tell you more about investing and give a guide on how to trade visit her on Email susandemorirs@gmail.com and her WhatsApp +1 (472) 218-4301
“To anyone looking down on the process of changing their life for the better—success takes the right mindset and the right guidance! Making a daily profit depends on who is managing your trade, and I’ve been fortunate to work with the best. Thanks to this amazing platform and expert signal management, I’ve made incredible profits. If you’re ready to take control of your financial future, reach out to Catherine E. Russell on Facebook—she will guide you every step of the way!”
Due to my experience, there are no magic in trading, having a strategy that ensures profits is the best you can do and that's not for novice, lost over $12k trading on my own. Investing creates a safe heaven for the future with the right investment choices that has at least 2% minimum risks and with the advice of an expert trader I earn 40k last month profits and interest are 💯guaranteed. Elizabeth Towles she’s one of the best traders in the crypto world, I have made so much profits from trading with her recommend..her info +1(563)279-8487
A friend of mine referred me to financial adviser BRENDA W. JEFFREY sometime ago and we got to talk about investment and money. I started investing with $130k and in the first 2 months, my portfolio was reading $274,800. Crazy right!, I decided to reinvest my profit and get more interesting. For over a year we have been working together making consistent profit I just bought my second home 2 weeks ago and care for my family. All thanks to BRENDA W. JEFFREY Dm on Facebook
SYTA .. STAY AWAY, it’s a trap ..!!
I lost thousands due to their multiple
Reverse splits..!! Factual statement
Recover Your Lost Funds with Expert Assistance from BSB Forensic
If you've fallen victim to fraudulent activities involving a company, broker, or account manager, don't lose hope. BSB Forensic specializes in helping individuals recover lost funds through thorough investigation and expert financial recovery strategies.
I personally recommend their trusted services—they successfully assisted me in recovering my lost funds, and I am confident they can help you too.
For more information and to start your recovery process today, visit Bsbforensic. com
yes
If you ever want to change or up your university grades, contact Cybergolden Hacker; he'll get it done and show proof of work done before payment. He's efficient, reliable, and affordable. He can also perform all sorts of hacks, including text, WhatsApp, password decryption, hacking any mobile phone, escaping bankruptcy, deleting criminal records, and the rest.
Email: cybergoldenhacker at gmail dot com
We made contac! The Ancient Alien Theorists were right!